Bedinvetmab ELISA Kit

Catalog No.

KDB91702

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.125 - 5,000 ng/mL

Sensitivity

33.12 ng/mL

Precision

CV<20%

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Alternative Names

ZTS-00508841, CAS: 2171034-69-6

Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)., PMID:40417367

Global pharmacovigilance reporting of the first monoclonal antibody for canine osteoarthritis: a case study with bedinvetmab (Librela™)., PMID:40343372

A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis., PMID:40196808

Answer re: A case of potential rapidly progressing osteoarthritis (RPOA) in a dog under bedinvetmab treatment., PMID:40158904

Re: Iff I, Hohermuth B, Bass D, Bass M. A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Veterinary Anaesthesia and Analgesia. 2024 Nov 29., PMID:40155266

Response to: Iff I, Hohermuth B, Bass D, Bass M (2025) A case of potential rapidly progressing osteoarthritis (RPOA) in a dog during bedinvetmab treatment. Vet Anesth Analg 52, 263-265., PMID:40155265

A Generic Detection Method for the Doping Control Analysis of Fc-Fusion Proteins and Monoclonal Antibodies in Equine Plasma., PMID:40033065

A case of potential rapidly progressing osteoarthritis in a dog during bedinvetmab treatment., PMID:39909782

Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study., PMID:39205806

Use of Bedinvetmab (Librela®) for Canine Osteoarthritis in France, Germany, Italy, Spain, and the UK: Quantitative Analysis of Veterinarian Satisfaction and Real-World Treatment Patterns., PMID:39123757

Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs., PMID:38885831

Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs., PMID:38580157

A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody., PMID:37541934

[New drugs for small animals in 2021]., PMID:35790168

A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis., PMID:34565678

Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs., PMID:34391918

Document Download

Bedinvetmab ELISA Kit.pdf